Company Description
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America.
The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians’ offices and over-the-counter channels.
It also provides contract development and manufacturing services to third parties. In addition, the company commercializes inFoods IBS product through physician-directed and laboratory-based channels, such as third-party reimbursement pathways.
Further, it is involved in the development and optimization of immunoassays, enzyme-linked immunosorbent assays, rapid diagnostic tests, and related diagnostic technologies; and research, development, commercialization of diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases.
Additionally, the company offers EZ detect colon disease home test; Aware Breast Self-Exam product; and hp+detect, a diagnostic test designed to detect Helicobacter pylori (H.
pylori) bacteria in the gastrointestinal tract. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 1971 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Zackary Irani |
Contact Details
Address: 17571 Von Karman Avenue Irvine, California 92614 United States | |
| Phone | 949 645 2111 |
| Website | biomerica.com |
Stock Details
| Ticker Symbol | BMRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0000073290 |
| CUSIP Number | 09061H406 |
| ISIN Number | US09061H4065 |
| Employer ID | 95-2645573 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Zackary S. Irani | Chief Executive Officer and Director |
| Allen C. Barbieri | Executive Vice-Chairman of the Board and Corporate Secretary |
| Lucy Liu Ph.D. | Director of Manufacturing and Technical Operations |
| Scott Madel | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 7, 2026 | EFFECT | Notice of Effectiveness |
| Oct 7, 2026 | EFFECT | Notice of Effectiveness |
| Sep 28, 2026 | 10-K/A | [Amend] Annual report |
| Sep 24, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 24, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 31, 2026 | 10-K | Annual Report |
| Aug 28, 2026 | SCHEDULE 13D | Filing |
| Aug 26, 2026 | 8-K | Current Report |
| Jun 4, 2026 | 8-K | Current Report |
| Apr 13, 2026 | 10-Q | Quarterly Report |